JPWO2021087050A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021087050A5 JPWO2021087050A5 JP2022524914A JP2022524914A JPWO2021087050A5 JP WO2021087050 A5 JPWO2021087050 A5 JP WO2021087050A5 JP 2022524914 A JP2022524914 A JP 2022524914A JP 2022524914 A JP2022524914 A JP 2022524914A JP WO2021087050 A5 JPWO2021087050 A5 JP WO2021087050A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- crizanlizumab
- concentration
- composition according
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962927716P | 2019-10-30 | 2019-10-30 | |
| US201962927720P | 2019-10-30 | 2019-10-30 | |
| US62/927,716 | 2019-10-30 | ||
| US62/927,720 | 2019-10-30 | ||
| US201962933692P | 2019-11-11 | 2019-11-11 | |
| US62/933,692 | 2019-11-11 | ||
| US201962936269P | 2019-11-15 | 2019-11-15 | |
| US62/936,269 | 2019-11-15 | ||
| PCT/US2020/057868 WO2021087050A1 (en) | 2019-10-30 | 2020-10-29 | Crizanlizumab containing antibody formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023501155A JP2023501155A (ja) | 2023-01-18 |
| JPWO2021087050A5 true JPWO2021087050A5 (ko) | 2023-11-07 |
Family
ID=73544317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022524914A Pending JP2023501155A (ja) | 2019-10-30 | 2020-10-29 | クリザンリズマブ含有抗体製剤 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220378912A1 (ko) |
| EP (1) | EP4051236A1 (ko) |
| JP (1) | JP2023501155A (ko) |
| KR (1) | KR20220092917A (ko) |
| CN (1) | CN114828826A (ko) |
| AU (1) | AU2020373017B2 (ko) |
| BR (1) | BR112022008097A2 (ko) |
| CA (1) | CA3158921A1 (ko) |
| CL (1) | CL2022001085A1 (ko) |
| CO (1) | CO2022005207A2 (ko) |
| EC (1) | ECSP22033601A (ko) |
| IL (1) | IL292403A (ko) |
| JO (1) | JOP20220097A1 (ko) |
| MX (1) | MX2022005044A (ko) |
| PE (1) | PE20221276A1 (ko) |
| TW (1) | TW202128221A (ko) |
| WO (1) | WO2021087050A1 (ko) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3501538A1 (en) | 2006-12-01 | 2019-06-26 | Novartis AG | Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases |
| JOP20190101A1 (ar) | 2016-11-03 | 2019-05-05 | Novartis Ag | أنظمة علاج |
| EP3624846B1 (en) * | 2017-05-16 | 2024-08-07 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan |
| EP3762424A1 (en) * | 2018-03-08 | 2021-01-13 | Novartis AG | Use of an anti-p-selectin antibody |
-
2020
- 2020-10-29 BR BR112022008097A patent/BR112022008097A2/pt unknown
- 2020-10-29 AU AU2020373017A patent/AU2020373017B2/en active Active
- 2020-10-29 TW TW109137726A patent/TW202128221A/zh unknown
- 2020-10-29 EP EP20811836.4A patent/EP4051236A1/en active Pending
- 2020-10-29 JO JOP/2022/0097A patent/JOP20220097A1/ar unknown
- 2020-10-29 IL IL292403A patent/IL292403A/en unknown
- 2020-10-29 CA CA3158921A patent/CA3158921A1/en active Pending
- 2020-10-29 MX MX2022005044A patent/MX2022005044A/es unknown
- 2020-10-29 WO PCT/US2020/057868 patent/WO2021087050A1/en active Application Filing
- 2020-10-29 JP JP2022524914A patent/JP2023501155A/ja active Pending
- 2020-10-29 CN CN202080075626.2A patent/CN114828826A/zh active Pending
- 2020-10-29 PE PE2022000689A patent/PE20221276A1/es unknown
- 2020-10-29 KR KR1020227017799A patent/KR20220092917A/ko unknown
- 2020-10-29 US US17/771,353 patent/US20220378912A1/en active Pending
-
2022
- 2022-04-26 CO CONC2022/0005207A patent/CO2022005207A2/es unknown
- 2022-04-27 EC ECSENADI202233601A patent/ECSP22033601A/es unknown
- 2022-04-28 CL CL2022001085A patent/CL2022001085A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7080263B2 (ja) | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 | |
| US20230047111A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| JP6059255B2 (ja) | ウイルス感染の処置における使用のためのテノホビルアラフェンアミドヘミフマル酸塩とコビシスタットを含む併用療法 | |
| JP2020518599A5 (ko) | ||
| JP2013511557A5 (ko) | ||
| JP2010511665A5 (ko) | ||
| KR20040088519A (ko) | 활성 제제 전달 시스템 및 활성 제제의 보호 및 투여 방법 | |
| WO2011012637A4 (en) | Subcutaneous anti-her2 antibody formulation | |
| CN117982637A (zh) | 抗rsv单克隆抗体配制品 | |
| DK2758076T3 (en) | COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR | |
| Maudgal et al. | Efficacy of (E)-5-(2-bromovinyl)-2′-deoxyuridine in the topical treatment of herpes simplex keratitis | |
| JP2022105056A (ja) | 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤 | |
| CN108350458B (zh) | 用豹蛙酶和/或两栖酶治疗病毒性结膜炎 | |
| JP2022539494A (ja) | 組換えタンパク質の安定な製剤 | |
| JP2005514414A5 (ko) | ||
| JPH0380772B2 (ko) | ||
| JPWO2021087050A5 (ko) | ||
| JP6051315B2 (ja) | 乾癬を処置するためのピドチモドの使用 | |
| CN111386103B (zh) | 稳定的艾博韦泰组合物 | |
| JP2770911B2 (ja) | 抗ウイルス医薬組成物 | |
| JPWO2020264333A5 (ko) | ||
| JPWO2021243298A5 (ko) | ||
| JPWO2021041989A5 (ko) | ||
| JPWO2021222355A5 (ko) | ||
| JPWO2020128864A5 (ko) |